Boston-based Beta Bionics said this week that the first patients have begun home use of dasiglucagon in a clinical trial of the company’s iLet bionic pancreas system for people with Type 1 diabetes. The iLet device features an autonomous, dual-chamber infusion pump that is powered by dosing algorithms. Using machine learning and data from a continuous […]
Diabetes
FDA warns against using ‘hacked’ diabetes devices
The FDA is warning the public against using unauthorized devices for diabetes management. After a report of a serious adverse event from a patient using an unauthorized device, the FDA is concerned about hacked devices used alone or with other authorized devices. In the report, a patient used an unauthorized device that received an electronic […]
Senseonics slides on Q1 loss, maintains outlook for 2019
Shares in Senseonics (NYSE:SENS) fell today after the diabetes-focused device maker posted first-quarter results that missed the consensus forecast on Wall Street. The Germantown, Md.-based company cited positive early feedback on the March launch of its Eversense Bridge Program, which is designed to improve patient access to the company’s Eversense continuous glucose monitoring system. Senseonics […]
Valeritas shares fall despite Street-topping Q1 sales
Shares in Valeritas (NSDQ:VLRX) are down more than 15% in after-hours trading despite the medtech firm releasing first quarter 2019 earnings that beat sales expectations and met loss-per-share consensus from Wall Street analysts. The Bridgewater, N.J.-based company posted losses of approximately $14.7 million, or 15¢ per share, on sales of $6.4 million for the three months […]
Medtronic touts CGM study results
Medtronic (NYSE:MDT) today announced the results of its SMILE study that investigated the safety and effectiveness of its MiniMed 640G system with SmartGuard. The study was conducted in adults who have type 1 diabetes and are more prone to severe hypoglycemia. The SMILE study tested the MiniMed 640G insulin pump with SmartGuide to prevent low glucose […]
Dance Biopharm Holdings raises $20.5M in private investment financing round
Privately-held Dance Biopharm said yesterday that it has completed a private equity financing round to secure about $20.5 million in gross proceeds. The financing round was insider-only with a number of institutional and individual accredited investors participating. Molex Ventures made a substantial equity investment in Dance Biopharm, according to the company. Molex has been involved in […]
Insulet posts Street-beating Q1 earnings
Shares in Insulet (NSDQ:PODD) are steady in after-hours trading after the diabetes-focused device maker posted first quarter earnings that topped Wall Street expectations. The Acton, Mass.-based company posted profits of approximately $4.4 million, or 7¢ per share, on sales of approximately $159.6 million for the three months ended March 31, seeing a swing from the red […]
Insulet cuts ribbon on new global headquarters
Insulet (NSDQ:PODD) hosted a ribbon cutting ceremony today to open its new global headquarters and manufacturing facility in Acton, Mass. The new facility is part of a $200 million investment in Massachusetts and is located on 26 acres of land. The site’s groundbreaking ceremony took place a year and a half ago and the investment has created […]
Dexcom shares steady after posting Street-beating Q1 earnings
Shares in Dexcom (NSDQ:DXCM) are steady in after-hours trading today after the diabetes-focused device maker posted first quarter 2019 earnings that topped loss-per-share and sales expectations. The San Diego-based company posted losses of $26.9 million, or 30¢ per share, on sales of $280.5 million for the three months ended March 31, seeing losses grow 11.2% while […]
Tandem Diabetes shares rise on lifted sales guidance in Q1 earnings
Shares in Tandem Diabetes Care (NSDQ:TNDM) have risen in after-hours trading today after the diabetes-focused device maker posted first quarter earnings with significantly lifted 2019 sales guidance. The San Diego-based company posted losses of approximately $23 million, or 40¢ per share, on sales of approximately $66 million for the three months ended March 31, seeing losses […]